NCT03373604View on ClinicalTrials.gov

Imaging Tau in Alzheimer's Disease and Normal Aging

PHASE2CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

December 11, 2017

Primary Completion Date

May 11, 2022

Study Completion Date

May 11, 2022

Conditions
Alzheimer Disease
Interventions
DRUG

18F-MK-6240

18F-MK-6240 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.

PROCEDURE

Lumbar Puncture (optional)

Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.

Trial Locations (1)

10032

Columbia University Medical Center, New York

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

Patrick Lao

OTHER

NCT03373604 - Imaging Tau in Alzheimer's Disease and Normal Aging | Biotech Hunter | Biotech Hunter